We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+2.44%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$290M
AUM Growth
-$2.78M
Cap. Flow
+$25.2M
Cap. Flow %
8.7%
Top 10 Hldgs %
94.95%
Holding
17
New
2
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ACET icon
Adicet Bio
ACET
+$23.2M
2
XFOR icon
X4 Pharmaceuticals
XFOR
+$2.01M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 89.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$7.81B
$82.1M 28.36%
4,168,718
– –
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$708M
$45.1M 15.56%
1,203,135
– –
ACET icon
3
Adicet Bio
ACET
$85.2M
$21M 7.24%
+100,962
New +$23.2M
VRNA
4
DELISTED
Verona Pharma
VRNA
$20.3M 7%
2,457,499
– –
SIEN
5
DELISTED
Sientra, Inc.
SIEN
$17.4M 5.99%
239,084
– –
NCNA
6
NuCana
NCNA
$5.49M
$16.6M 5.72%
667
– –
XCUR icon
7
Exicure
XCUR
$10.2M
$15.1M 5.23%
46,513
– –
SRRA
8
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$14.7M 5.08%
871,125
– –
SLNO
9
DELISTED
Soleno Therapeutics
SLNO
$13M 4.48%
686,840
– –
PRTK
10
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$7.33M 2.53%
1,041,131
– –
MTEM
11
DELISTED
Molecular Templates, Inc.
MTEM
$2.51M 0.87%
13,333
– –
XFOR icon
12
X4 Pharmaceuticals
XFOR
$375M
$1.96M 0.68%
+7,663
New +$2.01M
SYRE icon
13
Spyre Therapeutics
SYRE
$8.54B
$1.9M 0.65%
9,620
– –
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$595K 0.21%
131,036
– –
OBSV
15
DELISTED
ObsEva SA Ordinary Shares
OBSV
$286K 0.1%
87,999
– –
OCGN icon
16
Ocugen
OCGN
$416M
$48K 0.02%
7,111
– –

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q1 2021 Portfolio in Review

As of Q1 2021, Abingworth held 17 positions worth $290M, down 0.95% from $292M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Abingworth deployed $25.2M of net new capital in Q1 2021, opening 2 new positions. Its largest new stake was Adicet Bio: 100,962 shares worth $21M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 85% a quarter earlier.

  • Abingworth's largest Q1 2021 buy was Adicet Bio: 100,962 shares worth $21M.
  • Abingworth's ten largest holdings make up 95% of its $290M portfolio in Q1 2021.
  • Abingworth opened 2 new positions and closed 0 in Q1 2021.
  • Abingworth's portfolio value fell 0.95% quarter-over-quarter to $290M.

Based on Abingworth's 13F filing for Q1 2021, filed 17 May 2021.